XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile J. Hsu,C. Chong, L. Goon, J. Balayan,S. Wu, E. Johnson, G. Lorenzana, L. Bannen,L. Nguyen, C. Scheffold, P. Lamb,W. Xu, P. YuEuropean Journal of Cancer(2020)引用 5|浏览24暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要